US FDA cites Baxter for misleading Feiba promotion
This article was originally published in Scrip
Executive Summary
A promotional email for Baxter Healthcare's haemophilia treatment Feiba VH makes misleading safety and efficacy claims, the US FDAsaid. A "clinical thank you email" for the anti-inhibitor coagulant complex claims a 60% efficacy rate with one infusion, but this is inconsistent with the product's labelling. The promotion also minimises the fact that serious thrombotic events can occur with Feiba, and reported adverse events do not support the email's claim that Feiba is "well tolerated in 96-100% of infusions". Baxter said the email was a one-time communication used last year. The company is working to address the agency's concerns and ensure that appropriate contextual information is included in promotions to adequately support safety and efficacy claims.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.